• Selvita posted Q1 operating revenues of EUR 19.1 million, down from EUR 21.8 million a year earlier; EBITDA fell to EUR 2.7 million from EUR 3.6 million.
• EBITDA margin narrowed to 14% from 16.51% a year earlier, with operating costs reduced by about EUR 1.5 million under a cost-saving program.
• Drug Development commercial revenues rose 6% year over year to EUR 6.2 million, with segment EBITDA up 2% to EUR 1.7 million; Drug Discovery commercial revenues dropped to EUR 11.6 million from EUR 15.6 million, with segment EBITDA down to EUR 1 million from EUR 1.9 million.
• 2026 backlog stood at EUR 58.1 million as of May 18, down from EUR 58.9 million a year earlier, as Drug Discovery backlog slid 13% to EUR 35.3 million while Drug Development backlog climbed 15% to EUR 19.4 million.
• The group launched a strategic options review that may include a take-private transaction or accelerated M&A and organic investment, with Rothschild & Co hired as financial adviser.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Selvita SA published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605210113PR_NEWS_USPR_____LN65103) on May 21, 2026, and is solely responsible for the information contained therein.